AI Article Synopsis
- Several studies indicate that male breast cancer (MBC) differs biologically from female breast cancer, suggesting it should be viewed as a separate disease.
- In a study of 130 MBC specimens, FOXM1 was found to be overexpressed in 37% of samples, correlating with factors like tumor size, metastasis, and molecular subtypes.
- The results suggest that FOXM1 is an independent prognostic factor for overall survival in MBC patients, indicating its potential as a novel prognostic marker.
Article Abstract
Background: Several studies have outlined biological differences between female and male breast cancer (MBC) and concluded that MBC should be considered as an entirely separate disease. Whether FOXM1 has any indication for prognosis in MBC patients remains unknown. We sought to examine the expression levels of FOXM1 in MBC and to identify the relationship between FOXM1 expression and patient survival.
Patients And Methods: FOXM1 expression was evaluated in a total of 130 MBC specimens.
Results: FOXM1 was overexpressed in 37% of the MBC samples. FOXM1 overexpression was significantly associated with tumor size (p = 0.045), histological grade (p = 0.048), lymph node metastasis (p = 0.012), Ki-67 proliferation index (p = 0.016), and molecular subtypes (p < 0.001). Multivariate analyses indicated that FOXM1 was an independent prognostic factor for overall survival in MBC patients (p < 0.001, hazard ratio = 0.69 (0.43-0.96)).
Conclusions: Overexpression of FOXM1 was associated with well-established markers of poor prognosis; thus FOXM1 may represent a potential novel prognostic marker for MBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000458156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!